ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Méndez F, Muñoz A, Carrasquilla G, Jurado D, Arévalo-Herrera M, Cortese JF, Plowe CV, 2002. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol 156 :230–238.
-
2
Morrow RH, 2001. The epidemiology and control of malaria. Nelson KE, Williams CM, Graham NM, eds. Infectious Disease Epidemiology: Theory and Practice. Gaithersburg, MD: Aspen Publishers, 675–710.
-
3
Bishop A, 1954. The effect of sulphadiazine, proguanil and 2:4-diamino-6:7diisopropylpteridine upon gametocyte production in Plasmodium gallinaceum. Parasitology 45 :163–185.
-
4
Sucharit S, Surathin K, Tumrasvin W, Sucharit P, 1977. Chloroquine resistant Plasmodium falciparum in Thailand: susceptibility to Anopheles. J Med Assoc Thai 60 :648–654.
-
5
Sutherland C, Alloueche A, Curtis J, Drakeley CJ, Ord R, Durainsingh M, Greenwood BM, Pinder M, Warhust D, Targett GA, 2002. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg 67 :578–585.
-
6
Espinal LS, 1968. Visión Ecológica del Departamento del Valle del Cauca. Valle, Colombia: Ed. Universidad del Valle. 1968.
-
7
Méndez F, Carrasquilla G, Muñoz A, 2000. Risk factors associated with malaria infection in an urban setting. Trans R Soc Trop Med Hyg 94 :367–371.
-
8
Olano V, Carrasquilla G, Mendez F, 1997. Transmission of urban malaria in Buenaventura, Colombia: entomological features. Pan Am J Public Health 1 :287–294.
-
9
Quiñónez ML, Suarez MF, Fleming GA, 1987. Distribución y bionomía de los anofelinos de la costa Pacífica colombiana. Colomb Med 18 :19–24.
-
10
World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated falciparum Malaria. Geneva: World Health Organization. Technical Document 2003. WHO/HTM/RBM/2003.50.
-
11
Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of sulfadoxine-pyrimethamine use and resistance. J Infect Dis 176 :1590–1596.
-
12
Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arévalo-Herrera M, Herrera S, 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol 91 :4.
-
13
Hallett RL, Dunyo S, Ord R, Jawara M, Pinder M, Randall A, Alloueche A, Walraven G, Targett G, Alexander N, Sutherland CJ, 2006. Chloroquine/sulphadoxine-pyrimethamine for Gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials 1 :e15.
-
14
Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185 :380–388.
-
15
Clyde DF, 1966. Drug resistance of malaria parasites in Tanzania. East Afr Med J 43 :405–408.
-
16
Clyde DF, Shute GT, 1957. Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg 51 :505–513.
-
17
Peterson DS, Walliker D, Wellems TE, 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 85 :9114–9118.
-
18
Cortese JF, Caraballo A, Contreras CE, Plowe CV, 2002. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186 :999–1006.
-
19
Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T, 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science 305 :1124.
-
20
Hastings IM, 2004. The origins of antimalarial drug resistance. Trends Parasitol 20 :512–518.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 390 | 373 | 22 |
| Full Text Views | 244 | 4 | 0 |
| PDF Downloads | 67 | 5 | 0 |
Selection of Antifolate-Resistant Plasmodium falciparum by Sulfadoxine-Pyrimethamine Treatment and Infectivity to Anopheles Mosquitoes
Fabián Méndez
Fabián Méndez
Escuela de Salud Pública, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drugs Testing Center, Cali, Colombia; Universidad Nacional de Colombia, Sede Palmira, Colombia; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
Search for other papers by Fabián Méndez in
Current site
Google Scholar
PubMed
Search for other papers by Fabián Méndez in
Current site
Google Scholar
PubMed
Sócrates Herrera
Sócrates Herrera
Escuela de Salud Pública, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drugs Testing Center, Cali, Colombia; Universidad Nacional de Colombia, Sede Palmira, Colombia; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
Search for other papers by Sócrates Herrera in
Current site
Google Scholar
PubMed
Search for other papers by Sócrates Herrera in
Current site
Google Scholar
PubMed
Bermans Murrain
Bermans Murrain
Escuela de Salud Pública, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drugs Testing Center, Cali, Colombia; Universidad Nacional de Colombia, Sede Palmira, Colombia; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
Search for other papers by Bermans Murrain in
Current site
Google Scholar
PubMed
Search for other papers by Bermans Murrain in
Current site
Google Scholar
PubMed
Andrés Gutiérrez
Andrés Gutiérrez
Escuela de Salud Pública, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drugs Testing Center, Cali, Colombia; Universidad Nacional de Colombia, Sede Palmira, Colombia; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
Search for other papers by Andrés Gutiérrez in
Current site
Google Scholar
PubMed
Search for other papers by Andrés Gutiérrez in
Current site
Google Scholar
PubMed
Luz A. Moreno
Luz A. Moreno
Escuela de Salud Pública, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drugs Testing Center, Cali, Colombia; Universidad Nacional de Colombia, Sede Palmira, Colombia; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
Search for other papers by Luz A. Moreno in
Current site
Google Scholar
PubMed
Search for other papers by Luz A. Moreno in
Current site
Google Scholar
PubMed
María Manzano
María Manzano
Escuela de Salud Pública, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drugs Testing Center, Cali, Colombia; Universidad Nacional de Colombia, Sede Palmira, Colombia; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
Search for other papers by María Manzano in
Current site
Google Scholar
PubMed
Search for other papers by María Manzano in
Current site
Google Scholar
PubMed
Álvaro Muñoz
Álvaro Muñoz
Escuela de Salud Pública, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drugs Testing Center, Cali, Colombia; Universidad Nacional de Colombia, Sede Palmira, Colombia; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
Search for other papers by Álvaro Muñoz in
Current site
Google Scholar
PubMed
Search for other papers by Álvaro Muñoz in
Current site
Google Scholar
PubMed
Christopher V. Plowe
Christopher V. Plowe
Escuela de Salud Pública, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drugs Testing Center, Cali, Colombia; Universidad Nacional de Colombia, Sede Palmira, Colombia; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
Search for other papers by Christopher V. Plowe in
Current site
Google Scholar
PubMed
Search for other papers by Christopher V. Plowe in
Current site
Google Scholar
PubMed
Resistance-conferring mutations in dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) in Plasmodium falciparum are selected by treatment with sulfadoxine pyrimethamine (SP). We assessed the association between these mutations and transmission capacity of parasites to Anopheles mosquitoes on the Pacific coast of Colombia. Patients with uncomplicated P. falciparum malaria received SP treatment and were followed-up to compare the prevalence of DHFR and DHPS mutations before and after SP treatment. Membrane feeding assays were used to measure infectivity to mosquitoes of post-treatment gametocytes with and without these mutations. Per-protocol treatment efficacy was 95.0% (132 of 139). Gametocytes carrying resistance-conferring mutations were selected after SP treatment and were infective to mosquitoes. Seven days after treatment, infections with two DHFR mutations had a 10-fold higher probability of infecting mosquitoes than infections with no DHFR mutations (odds ratio = 10.23, P < 0.05). Low-level drug resistance mutations have the potential to enhance transmission of P. falciparum and spread resistant parasites.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Méndez F, Muñoz A, Carrasquilla G, Jurado D, Arévalo-Herrera M, Cortese JF, Plowe CV, 2002. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol 156 :230–238.
-
2
Morrow RH, 2001. The epidemiology and control of malaria. Nelson KE, Williams CM, Graham NM, eds. Infectious Disease Epidemiology: Theory and Practice. Gaithersburg, MD: Aspen Publishers, 675–710.
-
3
Bishop A, 1954. The effect of sulphadiazine, proguanil and 2:4-diamino-6:7diisopropylpteridine upon gametocyte production in Plasmodium gallinaceum. Parasitology 45 :163–185.
-
4
Sucharit S, Surathin K, Tumrasvin W, Sucharit P, 1977. Chloroquine resistant Plasmodium falciparum in Thailand: susceptibility to Anopheles. J Med Assoc Thai 60 :648–654.
-
5
Sutherland C, Alloueche A, Curtis J, Drakeley CJ, Ord R, Durainsingh M, Greenwood BM, Pinder M, Warhust D, Targett GA, 2002. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg 67 :578–585.
-
6
Espinal LS, 1968. Visión Ecológica del Departamento del Valle del Cauca. Valle, Colombia: Ed. Universidad del Valle. 1968.
-
7
Méndez F, Carrasquilla G, Muñoz A, 2000. Risk factors associated with malaria infection in an urban setting. Trans R Soc Trop Med Hyg 94 :367–371.
-
8
Olano V, Carrasquilla G, Mendez F, 1997. Transmission of urban malaria in Buenaventura, Colombia: entomological features. Pan Am J Public Health 1 :287–294.
-
9
Quiñónez ML, Suarez MF, Fleming GA, 1987. Distribución y bionomía de los anofelinos de la costa Pacífica colombiana. Colomb Med 18 :19–24.
-
10
World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated falciparum Malaria. Geneva: World Health Organization. Technical Document 2003. WHO/HTM/RBM/2003.50.
-
11
Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of sulfadoxine-pyrimethamine use and resistance. J Infect Dis 176 :1590–1596.
-
12
Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arévalo-Herrera M, Herrera S, 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol 91 :4.
-
13
Hallett RL, Dunyo S, Ord R, Jawara M, Pinder M, Randall A, Alloueche A, Walraven G, Targett G, Alexander N, Sutherland CJ, 2006. Chloroquine/sulphadoxine-pyrimethamine for Gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials 1 :e15.
-
14
Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185 :380–388.
-
15
Clyde DF, 1966. Drug resistance of malaria parasites in Tanzania. East Afr Med J 43 :405–408.
-
16
Clyde DF, Shute GT, 1957. Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg 51 :505–513.
-
17
Peterson DS, Walliker D, Wellems TE, 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 85 :9114–9118.
-
18
Cortese JF, Caraballo A, Contreras CE, Plowe CV, 2002. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186 :999–1006.
-
19
Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T, 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science 305 :1124.
-
20
Hastings IM, 2004. The origins of antimalarial drug resistance. Trends Parasitol 20 :512–518.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 390 | 373 | 22 |
| Full Text Views | 244 | 4 | 0 |
| PDF Downloads | 67 | 5 | 0 |